TYRNOVO
TyrNovo is developing NT219, a small molecule originally developed by Dr. Hadas Reuveni and Prof. Alexander Levitzki at the Hebrew University, and exclusively licensed from Yissum, the Hebrew University Research Development Company. TyrNovo demonstrated the potential of NT219 to overcome resistance to multiple anti-cancer drugs, by using the Patient-Derived Xenograft (PDX) models, in collaboration with Prof. Izhak Haviv from the Bar-Ilan University and Prof. M. Stemmer from Clalit HMO.
TYRNOVO
Industry:
Biotechnology Oncology
Address:
Herzliya, Tel Aviv, Israel
Country:
Israel
Website Url:
http://www.tyrnovo.co.il
Status:
Closed
Technology used in webpage:
Domain Not Resolving
Current Employees Featured
Founder
More informations about "TyrNovo"
TyrNovo - Crunchbase Company Profile & Funding
TyrNovo is developing NT219, a small molecule originally developed by Dr. Hadas Reuveni and Prof. Alexander Levitzki at the Hebrew University, and exclusively licensed from Yissum, the …See details»
TYRNOVO LTD Company Profile | REHOVOT, Shfella Area, Israel ...
Find company research, competitor information, contact details & financial data for TYRNOVO LTD of REHOVOT, Shfella Area. Get the latest business insights from Dun & Bradstreet.See details»
TyrNovo Company Profile 2024: Valuation, Investors, Acquisition
TyrNovo General Information Description. Developer of small molecular drugs designed to treat cancer and inflammation diseases. The company's small molecular drugs are used for the …See details»
מידע על טירנובו בע"מ - אתר החברות הישראלי
מידע חינם על טירנובו בע"מ ח.פ 514964055 - מרכז השירות והמידע הנלקח מאתרי הממשלה ומאגר החברות הממשלתי. מידע על טירנובו בע"מ כתובת, טלפון האם החברה בפרוק, מוגבלת או פעילה.See details»
Tyrnovo Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Tyrnovo Ltd. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, and 11 literature, Disease Domain:Neoplasms, Technology Platform ...See details»
TYRNOVO LTD - Israel Company Information
All items in the basic report plus:A complete record of all correspondence and official filings with the Israel Companies Authority. This information source can return hundreds of pages of …See details»
TyrNovo - Ownership and Business Overview - Mergr
TyrNovo Ltd. Israel, www.tyrnovo.co.il. ... TyrNovo Ltd. is a developer of NT219 to overcome resistance to multiple anti-cancer drugs, by using the Patient-Derived Xenograft (PDX) …See details»
טירנובו בע"מ / TYRNOVO LTD - 514964055 - CheckId
תמצית מידע עבור חברה טירנובו בע"מ - 514964055 אופנהיימר 4 ,רחובותSee details»
Tyrnovo Ltd.:Company Profile & Technical Research,Competitor …
Tyrnovo Ltd. is a company that provides Small molecule, Medicine, Research development and more. Tyrnovo Ltd. is headquartered in Israel . Tyrnovo Ltd. has a total of 31 patentsSee details»
TyrNovo - Products, Competitors, Financials, Employees, …
TyrNovo is a developer of novel small molecules in the immuno-oncology therapeutic field, including NT219, a small molecule which has displayed potent anti-tumor effects and …See details»
טירנובו , ייצור חומרים תרופתיים ברחובות - דנסגייד
כל המידע שאתם צריכים על טירנובו בע"מ, ייצור חומרים תרופתיים ברחובות – היכנסו לדנסגייד מדריך העסקים המוביל בישראל מבית דן אנד ברדסטריט.See details»
TyrNovo - Israeli Startup | Startup Nation Finder
Dec 9, 2015 TyrNovo is developing a cancer treatment that eliminates a key protein, an approach that has the potential to improve cancer therapy, prevent drug resistance, and …See details»
TyrNovo Ltd Company Insights, Tech Stack, and Competitors
Find useful insights on TyrNovo Ltd’s company details, tech stack, news alerts, competitors and more. Use 6sense to connect with top decision-makers at TyrNovo Ltd. ... tyrnovo.co.il. Type. …See details»
TyrNovo - Company Profile - Tracxn
Dec 25, 2023 TyrNovo - Insulin Receptor Substrate targeted drugs for cancer & drug resistance. from 1 investor. TyrNovo has 2792 competitors.See details»
השקעה בסיכון גבוה: כיטוב פארמה רוכשת חברת ביומד ב-3.8 מיליון …
Jan 15, 2017 כיטוב רוכשת את רוב המניות בחברה הפרטית 'TyrNovo', המפתחת מולקולות בתחום הטיפולים האימונו-אונקולוגיים. כיטוב פארמה תשלם 2 מיליון דולר ובנוסף תעביר מניות שלה בשווי של 1.8 מיליון דולר …See details»
TyrNovo - Contacts, Employees, Board Members, Advisors & Alumni
TyrNovo is a developer of novel small molecules in the immuno-oncology therapeutic field. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. …See details»
Tyrnovo Ltd.: Drug pipelines, Patents, Clinical trials - Synapse
Sep 3, 2023 Explore Tyrnovo Ltd. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, Disease Domain:Nervous System Diseases, Neoplasms, Endocrinology ...See details»
TyrNovo - Suggested Companies | Startup Nation Finder
Find out more about TyrNovo's suggested companies. Q1 2024 Israeli Tech ReportSee details»
Hadas Reuveni - Chief Technology Officer & Co-Founder
Dr. Reuveni, a co-inventor of the TyrNovo technology, received her Ph.D., Summa Cum Laude, for anti-cancer drug discovery from the Hebrew University of Jerusalem. She has 15 years of …See details»
KD Law Offices - אנו גאים בלקוחה שלנו, כיטוב פארמה, על...
Jan 16, 2017 אנו גאים בלקוחה שלנו, כיטוב פארמה, על התרחבותה לתחום האימונו-אונקולוגי באמצעות רכישת השליטה ב-TryNovo, חברה פרטית המפתחת מולקולות המסייעות למניעת עמידות...See details»